The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Maximum Tolerated Dose

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Maximum Tolerated Dose


Psychiatry related information on Maximum Tolerated Dose


High impact information on Maximum Tolerated Dose


Chemical compound and disease context of Maximum Tolerated Dose


Biological context of Maximum Tolerated Dose


Anatomical context of Maximum Tolerated Dose


Associations of Maximum Tolerated Dose with chemical compounds


Gene context of Maximum Tolerated Dose


Analytical, diagnostic and therapeutic context of Maximum Tolerated Dose


  1. Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. Pluda, J.M., Shay, L.E., Foli, A., Tannenbaum, S., Cohen, P.J., Goldspiel, B.R., Adamo, D., Cooper, M.R., Broder, S., Yarchoan, R. J. Natl. Cancer Inst. (1993) [Pubmed]
  2. Deprenyl in Parkinson's disease. Lees, A.J., Shaw, K.M., Kohout, L.J., Stern, G.M., Elsworth, J.D., Sandler, M., Youdim, M.B. Lancet (1977) [Pubmed]
  3. Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis. Angelico, M., Carli, L., Piat, C., Gentile, S., Rinaldi, V., Bologna, E., Capocaccia, L. Gastroenterology (1993) [Pubmed]
  4. Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Chou, T.C., Zhang, X.G., Balog, A., Su, D.S., Meng, D., Savin, K., Bertino, J.R., Danishefsky, S.J. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  5. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Vahdat, L., Wong, E.T., Wile, M.J., Rosenblum, M., Foley, K.M., Warrell, R.P. Blood (1994) [Pubmed]
  6. No response to high-dose muscarinic agonist therapy in Alzheimer's disease. Mouradian, M.M., Mohr, E., Williams, J.A., Chase, T.N. Neurology (1988) [Pubmed]
  7. Establishing the maximum tolerated dose of lesopitron in patients with generalized anxiety disorder: a bridging study. Sramek, J.J., Fresquet, A., Marion-Landais, G., Hourani, J., Jhee, S.S., Martinez, L., Jensen, C.M., Bolles, K., Carrington, A.T., Cutler, N.R. Journal of clinical psychopharmacology. (1996) [Pubmed]
  8. Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study. Cutler, N.R., Jhee, S.S., Cyrus, P., Bieber, F., TanPiengco, P., Sramek, J.J., Gulanski, B. Life Sci. (1998) [Pubmed]
  9. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Charache, S., Terrin, M.L., Moore, R.D., Dover, G.J., Barton, F.B., Eckert, S.V., McMahon, R.P., Bonds, D.R. N. Engl. J. Med. (1995) [Pubmed]
  10. Human TNF mutants with selective activity on the p55 receptor. Van Ostade, X., Vandenabeele, P., Everaerdt, B., Loetscher, H., Gentz, R., Brockhaus, M., Lesslauer, W., Tavernier, J., Brouckaert, P., Fiers, W. Nature (1993) [Pubmed]
  11. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study. Lichtman, S.M., Ratain, M.J., Van Echo, D.A., Rosner, G., Egorin, M.J., Budman, D.R., Vogelzang, N.J., Norton, L., Schilsky, R.L. J. Natl. Cancer Inst. (1993) [Pubmed]
  12. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. Hochster, H., Liebes, L., Wadler, S., Oratz, R., Wernz, J.C., Meyers, M., Green, M., Blum, R.H., Speyer, J.L. J. Natl. Cancer Inst. (1992) [Pubmed]
  13. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Ware, R.E., Eggleston, B., Redding-Lallinger, R., Wang, W.C., Smith-Whitley, K., Daeschner, C., Gee, B., Styles, L.A., Helms, R.W., Kinney, T.R., Ohene-Frempong, K. Blood (2002) [Pubmed]
  14. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Mier, J.W., Vachino, G., Klempner, M.S., Aronson, F.R., Noring, R., Smith, S., Brandon, E.P., Laird, W., Atkins, M.B. Blood (1990) [Pubmed]
  15. A controlled trial of the effect of 4-hydroxypyrazolopyrimidine (allopurinol) on the toxicity of a single bolus dose of 5-fluorouracil. Woolley, P.V., Ayoob, M.J., Smith, F.P., Lokey, J.L., DeGreen, P., Marantz, A., Schein, P.S. J. Clin. Oncol. (1985) [Pubmed]
  16. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer. Shinkai, T., Arioka, H., Kunikane, H., Eguchi, K., Sasaki, Y., Tamura, T., Ohe, Y., Oshita, F., Nishio, M., Karato, A. Cancer Res. (1994) [Pubmed]
  17. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. Elias, A.D., Ayash, L.J., Eder, J.P., Wheeler, C., Deary, J., Weissman, L., Schryber, S., Hunt, M., Critchlow, J., Schnipper, L. J. Clin. Oncol. (1991) [Pubmed]
  18. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Ghofrani, H.A., Wiedemann, R., Rose, F., Schermuly, R.T., Olschewski, H., Weissmann, N., Gunther, A., Walmrath, D., Seeger, W., Grimminger, F. Lancet (2002) [Pubmed]
  19. Use of alpha interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation. Higano, C.S., Raskind, W.H., Singer, J.W. Blood (1992) [Pubmed]
  20. Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells. Schilder, R.J., Johnson, S., Gallo, J., Kindsfather, S., Rogers, B., Bookman, M.A., Millenson, M.M., Boente, M., Rosenblum, N., Litwin, S., Ozols, R.F. J. Clin. Oncol. (1999) [Pubmed]
  21. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. Alatrash, G., Hutson, T.E., Molto, L., Richmond, A., Nemec, C., Mekhail, T., Elson, P., Tannenbaum, C., Olencki, T., Finke, J., Bukowski, R.M. J. Clin. Oncol. (2004) [Pubmed]
  22. Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia. Seiter, K., Feldman, E.J., Halicka, H.D., Traganos, F., Darzynkiewicz, Z., Lake, D., Ahmed, T. J. Clin. Oncol. (1997) [Pubmed]
  23. Intensive outpatient adjuvant therapy for breast cancer: results of dose escalation and quality of life. Swain, S.M., Rowland, J., Weinfurt, K., Berg, C., Lippman, M.E., Walton, L., Egan, E., King, D., Spertus, I., Honig, S.F. J. Clin. Oncol. (1996) [Pubmed]
  24. Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats. Ohno, S., Siddik, Z.H., Baba, H., Stephens, L.C., Strebel, F.R., Wondergem, J., Khokhar, A.R., Bull, J.M. Cancer Res. (1991) [Pubmed]
  25. Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent. Rowinsky, E.K., Long, G.S., Noe, D.A., Grochow, L.B., Bowling, M.K., Sartorius, S.E., Donehower, R.C. Clin. Cancer Res. (1997) [Pubmed]
  26. Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity. Linette, G.P., Zhang, D., Hodi, F.S., Jonasch, E.P., Longerich, S., Stowell, C.P., Webb, I.J., Daley, H., Soiffer, R.J., Cheung, A.M., Eapen, S.G., Fee, S.V., Rubin, K.M., Sober, A.J., Haluska, F.G. Clin. Cancer Res. (2005) [Pubmed]
  27. An adenosine A1 receptor agonist, R(-)-N-(2-phenylisopropyl)-adenosine (PIA), but not adenosine itself, acts as a therapeutic preconditioning-mimetic agent in rabbits. Hale, S.L., Bellows, S.D., Hammerman, H., Kloner, R.A. Cardiovasc. Res. (1993) [Pubmed]
  28. Role of administration route in the therapeutic efficacy of doxifluridine. Trave, F., Canobbio, L., Au, J.L., Rustum, Y.M. J. Natl. Cancer Inst. (1987) [Pubmed]
  29. Oral metoclopramide with or without diphenhydramine: potential for prevention of late nausea and vomiting induced by cisplatin. Grunberg, S.M., Ehler, E., McDermed, J.E., Akerley, W.L. J. Natl. Cancer Inst. (1988) [Pubmed]
  30. Phase I/II study of cyclophosphamide, doxorubicin, fluorouracil, and leucovorin for treatment of metastatic adenocarcinoma. Parnes, H.L., Abrams, J.S., Tait, N., Minford, J., Allen, S.L., Duggan, D., Aisner, J. J. Natl. Cancer Inst. (1991) [Pubmed]
  31. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. Eder, J.P., Antman, K., Elias, A., Shea, T.C., Teicher, B., Henner, W.D., Schryber, S.M., Holden, S., Finberg, R., Chritchlow, J. J. Natl. Cancer Inst. (1988) [Pubmed]
  32. Failure of high-dose leucovorin to improve therapy with the maximally tolerated dose of 5-fluorouracil: a murine study with clinical relevance? Martin, D.S., Stolfi, R.L., Colofiore, J.R. J. Natl. Cancer Inst. (1988) [Pubmed]
  33. Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy. Atkins, M.B., Vachino, G., Tilg, H.J., Karp, D.D., Robert, N.J., Kappler, K., Mier, J.W. J. Clin. Oncol. (1992) [Pubmed]
  34. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. Rudek, M.A., Figg, W.D., Dyer, V., Dahut, W., Turner, M.L., Steinberg, S.M., Liewehr, D.J., Kohler, D.R., Pluda, J.M., Reed, E. J. Clin. Oncol. (2001) [Pubmed]
  35. Phase I study of recombinant human CD40 ligand in cancer patients. Vonderheide, R.H., Dutcher, J.P., Anderson, J.E., Eckhardt, S.G., Stephans, K.F., Razvillas, B., Garl, S., Butine, M.D., Perry, V.P., Armitage, R.J., Ghalie, R., Caron, D.A., Gribben, J.G. J. Clin. Oncol. (2001) [Pubmed]
  36. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Slaton, J.W., Perrotte, P., Inoue, K., Dinney, C.P., Fidler, I.J. Clin. Cancer Res. (1999) [Pubmed]
  37. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine. Kokkinakis, D.M., Ahmed, M.M., Chendil, D., Moschel, R.C., Pegg, A.E. Clin. Cancer Res. (2003) [Pubmed]
  38. Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft. Pratesi, G., Petrangolini, G., Tortoreto, M., Addis, A., Belluco, S., Rossini, A., Selleri, S., Rumio, C., Menard, S., Balsari, A. Cancer Res. (2005) [Pubmed]
  39. Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial. Kent, E., Sandler, H., Montie, J., Lee, C., Herman, J., Esper, P., Fardig, J., Smith, D.C. J. Clin. Oncol. (2004) [Pubmed]
  40. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. Abraham, J., Agrawal, M., Bakke, S., Rutt, A., Edgerly, M., Balis, F.M., Widemann, B., Davis, L., Damle, B., Sonnichsen, D., Lebwohl, D., Bates, S., Kotz, H., Fojo, T. J. Clin. Oncol. (2003) [Pubmed]
  41. Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation. Mitchell, R.B., Moschel, R.C., Dolan, M.E. Cancer Res. (1992) [Pubmed]
  42. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). Blaney, S.M., Boyett, J., Friedman, H., Gajjar, A., Geyer, R., Horowtiz, M., Hunt, D., Kieran, M., Kun, L., Packer, R., Phillips, P., Pollack, I.F., Prados, M., Heideman, R. J. Clin. Oncol. (2005) [Pubmed]
WikiGenes - Universities